DHEA & Fertility
The general dose of DHEA is 75mg daily, which is split into three 25mg doses (to avoid the development of an upset stomach). The treatment is usually started at least 6 weeks prior to the start of IVF cycles, so that DHEA has enough time to affect the ovarian environment for the folliclefollicle that are still small and growing. Supplementation is stopped once a woman has conceived, as the body produces enough DHEA during pregnancy. Because some women take longer than others to convert DHEA into androgensandrogens , the time to get pregnant after DHEA supplementation will be different for each woman.
It is important to note that DHEA alone is unlikely to be effective for women with diminished ovarian reserve who are trying to conceive. To maximize every woman's pregnancy chances, CHR uses DHEA within a well-designed fertility treatment framework. This framework includes ovarian stimulationovarian stimulation protocol tailored to each woman's needs as well as proper management of any contributing infertility factors.
One example of how CHR uses DHEA within a carefully defined fertility treatment framework is testosteronetestosterone monitoring: CHR’s recent research has shown that women whose androgen levels rise while on DHEA supplementation have higher pregnancy rates than those whose androgen levels remain low, even with DHEA. CHR physicians now closely monitor the patients’ androgen (testosterone) levels in order to start their IVF cycles when the androgen levels are within the optimal range.
DHEA should always be taken under the supervision of a physician, as the hormone can interact with some prescription drugs and affect some medical conditions like diabetes, mood disorders, and estrogen-sensitive cancers.
Read more about DHEA Treatment
DHEA (or dehydroepiandrosterone) is a naturally existing hormone that the female body converts into...
CHR studies have found, and others have confirmed, that DHEA restores healthy...
Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned reproductive endocrinologist, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.
Last Updated: October 8, 2018